ConductScience.org, home

Trial · NCT07877363

Artificial Intelligence-Powered Virtual Reality Exposure Therapy for OCD in College Students: A Proof-of-Concept Study

NCT07877363, Not applicable, Not yet recruiting, University of California, San Diego

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. Artificial Intelligence-Powered Virtual Reality Exposure Therapy for OCD in College Students: A Proof-of-Concept Study. Trials, record NCT07877363. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07877363

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Artificial Intelligence-Powered Virtual Reality Exposure Therapy for OCD in College Students: A Proof-of-Concept Study
NCT number
NCT07877363
Status
Not yet recruiting
Phases
Not applicable
Enrollment
24 participants, estimated
Lead sponsor
University of California, San Diego
Conditions
Obsessive Compulsive Disorder (OCD)
Interventions
Traditional Exposure and Response Prevention (ERP), Artificial Intelligence-Powered Virtual Reality Exposure Therapy (AI-VRET)
First posted
2026-10-16
Last updated
2026-10-16

Source ClinicalTrials.gov

Registered outcomes8

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryYale-Brown Obsessive Compulsive Scale-II (Y-BOCS-II)Visits 1 (baseline) & 14 (post-treatment assessment, approximately 14 weeks following baseline)
SecondaryFlorida Obsessive-Compulsive Inventory (FOCI)Visits 1 (baseline) & 14 (post-treatment assessment, approximately 14 weeks following baseline)
SecondaryAdult OCD Impact Scale (OCD-IS):Visits 1 (baseline) & 14 (post-treatment assessment, approximately 14 weeks following baseline)
SecondarySheehan Disability Scale (SDS)Visits 1 (baseline) & 14 (post-treatment assessment, approximately 14 weeks following baseline)
SecondaryGeneralized Anxiety Disorder-7 (GAD-7):Visits 1-14 (all study visits). Visit 1 is at baseline, and subsequent visits are approximately one week apart. The final visit is approximately 14 weeks after baseline.
SecondaryPatient Health Questionnaire-9 (PHQ-9)Visits 1-14 (all study visits). Visit 1 is at baseline, and subsequent visits are approximately one week apart. The final visit is approximately 14 weeks after baseline.
SecondaryPresence Questionnaire (PQ)Visits 2-13. Visit 2 is approximately one week following baseline, and subsequent visits are approximately one week apart. Visit 13 is approximately 13 weeks following baseline.
SecondaryCybersickness in Virtual Reality Questionnaire (CSQ-VR)Visits 2-13. Visit 2 is approximately one week following baseline, and subsequent visits are approximately one week apart. Visit 13 is approximately 13 weeks following baseline.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07877363

GET https://conductscience.org/api/trials/v1/NCT07877363/registered